
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc is developing innovative cannabinoid-based formulations with investigational drug assets, particularly targeting Alzheimer's disease, which exhibit potential efficacy in combating key disease hallmarks. The company's current valuation reflects an attractive investment opportunity, highlighted by a notable increase in price target based on a net present value analysis, suggesting substantial upside from the existing share price. Additionally, upcoming positive data and advancements in the company’s research are anticipated to act as catalysts to further enhance stock performance.
Bears say
IGC Pharma Inc reported a net loss of $1.6 million, resulting in an earnings per share (EPS) of $(0.02), which aligns with both the company's and consensus estimates but indicates ongoing financial challenges. Key risks impacting IGC Pharma's outlook include significant balance sheet and liquidity concerns, potential failures in demonstrating the safety and efficacy of its investigational drug candidates, and hurdles related to regulatory approvals, commercialization, and reimbursement. Additionally, increased competition, fluctuating macroeconomic conditions, and changing investor sentiment towards biotech stocks further compound the negative outlook for the company's stock.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares